Inovio Pharmaceuticals Inc (NASDAQ: INO) is having an incredibly strong day in the market today, and for good reason. The comapny announced that its data had been highlighted in a reputable medical journal. Of course, the news excited investors, sending the stock screaming for the top. Today, we’ll talk about:
- The news;
- what we’re seeing from INO stock as a result; and
- what we’ll be watching for ahead.
INO Data Was Featured In A Trusted Medical Journal
As mentioned above, Inovio Pharmaceuticals is having an incredibly strong day in the market today after announcing that a paper published in a major cancer journal detailed the results of a patient with head and neck cancer treated with MEDI0457. The paper outlined that the patient achieved and sustained a complete response on treatment with a subsequent PD-1 checkpoint inhibitor.
In the study sponsored by INO of 22 patients with head and neck squamous cell carcinoma, 01% showed T cell activity in the blood or tissue. MEDI0457, previously known as INO-3112 was licensed to MedImmune in 2015. In a statement, Dr. J. Joseph Kim, CEO and Presdient at INO, had the following to offer:
We are buoyed by the study as it lends support to all of our HPV and oncology programs. These data demonstrated that Inovio’s technology based in MEDI0457 can generate durable HPV16/18 antigen-specific peripheral and tumor immune responses. The study supports our belief that this approach may be used as a complementary strategy to PD-1/PD-L1 inhibition in HPV-associated head and neck and other types of cancer to improve therapeutic outcomes. Inovio is collaborating with MedImmune (w/ MEDI0457) as well as Genentech and Regeneron (w/ INO-5401) in efficacy trials coupling Inovio’s DNA-based cancer immunotherapies with checkpoint inhibitors designed to increase response rates with data expected in 2019.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. In the case of INO, the news was overwhelmingly positive. With its data being featured in a major medical journal, all eyes are on the company and its asset. So, it comes as no surprise to see that excited investors are sending the stock screaming for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (11:06), INO is trading at $6.05 per share after a gain of $0.70 per share or 13.02% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on INO. In particular, we’re interested in following the continued development of the company’s impressive pipeline of products. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!